SMS Lifesciences India Limited — Important, 14-07-2025: Updates

SMS Lifesciences reports robust FY25 performance with consolidated revenue climbing 12.67% to ₹344.72 Cr and PAT surging 196.04% to ₹18.73 Cr. Q4 profitability saw a dip due to a ₹4.34 Cr provision for doubtful debts. Operationally, the company achieved successful USFDA audits for its Mahi Drugs subsidiary (no observations) and its main Kazipalli plant (one procedural observation) in early 2025. Strategic initiatives include a ₹145 Cr CAPEX for growth, backward integration for cost synergies, and plans to expand the product portfolio to 50+ by FY2028, backed by ₹6.30 Cr in R&D spend and 7 DMF filings.